newsfilter
← Latest News
GlobeNewswire·

Prelude Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Lead candidate from mutant selective JAK2V617F JH2 inhibitor program advancing with IND filing expected in the first quarter of 2026 Lead candidate from oral KAT6A selective degrader program advancing with IND filing